Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
National Institute of Allergy and Infectious Diseases (NIAID)
Andre C Kalil; Thomas F Patterson; Aneesh K Mehta; Kay M Tomashek; Cameron R Wolfe; Varduhi Ghazaryan; Vincent C Marconi; Guillermo M Ruiz-Palacios; Lanny Hsieh; Susan Kline; Victor Tapson; Nicole M Iovine; Mamta K Jain; Daniel A Sweeney; Hana M El Sahly; Angela R Branche; Justino Regalado Pineda; David C Lye; Uriel Sandkovsky; Anne F Luetkemeyer; Stuart H Cohen; Robert W Finberg; Patrick E H Jackson; Babafemi Taiwo; Catharine I Paules; Henry Arguinchona; Nathaniel Erdmann; Neera Ahuja; Maria Frank; Myoung-Don Oh; Eu-Suk Kim; Seow Y Tan; Richard A Mularski; Henrik Nielsen; Philip O Ponce; Barbara S Taylor; LuAnn Larson; Nadine G Rouphael; Youssef Saklawi; Valeria D Cantos; Emily R Ko; John J Engemann; Alpesh N Amin; Miki Watanabe; Joanne Billings; Marie-Carmelle Elie; Richard T Davey; Timothy H Burgess; Jennifer Ferreira; Michelle Green; Mat Makowski; Anabela Cardoso; Stephanie de Bono; Tyler Bonnett; Michael Proschan; Gregory A Deye; Walla Dempsey; Seema U Nayak; Lori E Dodd; John H Beigel; ACTT-2 Study Group Members